Phio Pharmaceuticals Corp. (PHIO): Nasdaq/NYSE listing notice — Phio Pharmaceuticals receives Nasdaq delisting notice for bid price below $1.00

January 24, 2024, Phio Pharmaceuticals Corp. (the “Company”) received written notice (the “Notification Letter”) from The Nasdaq Capital Market (“Nasdaq”) stating that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Rule”) because the Company’s common stock failed to maintain a minimum closing bid price of $1.00 for 30 consecutive business days. The Notice has no immediate effect on the Nasdaq listing or trading of the Company’s common stock The Notification Letter provides an initial 180 calendar day period, or until July 22, 2024, in which to reg